Disc Medicine Raising $350M in Stock Days After Landmark Phase 3 Win
IRON sits 95% above its 52-week low of $40 on elevated volume (14× avg).
Summary
Disc launched a $350M underwritten public offering of common stock and pre-funded warrants, with a 30-day option for up to $52.5M more. That's roughly 12% of the company's market value raised in one shot, a meaningful dilution for existing holders. The timing is telling: it comes hours after the company reported the pivotal Phase 3 APOLLO trial of bitopertin hit all primary and secondary endpoints, and proceeds are earmarked for potential commercialization of bitopertin in EPP and XLP plus pre-commercialization work on other candidates. The company already had $718M in cash with runway into 2029 as of the Q2 report, so this raise is about funding a launch build-out rather than plugging a hole. Pricing terms aren't set yet — the discount at which the deal clears will be the read on demand after today's rally.
At the time of this announcement, IRON was trading at $78.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $40.00 to $99.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.